B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of ...
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...
Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.
B. Riley Financial Inc. suspended dividends on a pair of its preferred shares, holding off on cash payments to some investors ...
I have covered B. Riley Financial, Inc. or "B. Riley" (NASDAQ:RILY, NASDAQ:RILYL, NASDAQ:RILYP, NASDAQ:RILYM, NASDAQ:RILYK, NASDAQ:RILYN, NASDAQ:RILYG, NASDAQ:RILYT ...
The deferral affects B. Riley’s 6.875% Series A and 7.375% Series B preferred stock, according to a statement Monday. Dividends on those preferreds cost the company $2 million in the second ...
LOS ANGELES, Jan. 21, 2025 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ: RILY) ("B. Riley" or the "Company"), a diversified financial services company, today ...
Alcoa Co. (NYSE:AA – Free Report) – Stock analysts at B. Riley boosted their FY2024 EPS estimates for shares of Alcoa in a research report issued on Tuesday, January 21st. B. Riley analyst L.